<DOC>
	<DOCNO>NCT00216723</DOCNO>
	<brief_summary>This multicenter , open-label , prospective study Aripiprazole use patient schizophrenia bipolar disorder .</brief_summary>
	<brief_title>Efficacy Safety Aripiprazole Patients With Schizophrenia Bipolar Disorder</brief_title>
	<detailed_description>This multicenter , open-label , prospective study Aripiprazole use patient schizophrenia bipolar disorder . Qualified schizophrenia patient enrol 12-week treatment phase Aripiprazole physician 's assessment . Qualified bipolar disorder patient enrol 8-week treatment phase Aripiprazole physician 's assessment . This study continue 6 year . The final report Aripiprazole PMS submit KFDA December 28 , 2009 .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Patient schizophrenia schizoaffective disorder bipolar disorder accord DSMIV criterion Age : 18 year age Unqualified patient judge study investigator ( )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Aripiprazole</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Bipolar Disorder</keyword>
</DOC>